Tavaborole Solution
NDC 21922-020
Product Information
Tavaborole (tavaborole topical solution, 5%) is a ANDA-approved product labeled by Encube Ethicals, Inc.. This medication is used to treat toenail infection caused by fungus. It is supplied as a solution for topical administration. This product entry covers the primary NDC 21922-020 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 21922-020?
What are the uses of this product?
What are Active Ingredients of this product?
- TAVABOROLE 43.5 mg/mL - has antifungal activity; structure in first source
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TAVABOROLE (UNII: K124A4EUQ3)
- TAVABOROLE (UNII: K124A4EUQ3) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ALCOHOL (UNII: 3K9958V90M)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- EDETATE CALCIUM DISODIUM (UNII: 25IH6R4SGF)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1543177 - tavaborole 5 % Topical Solution
- RxCUI: 1543177 - tavaborole 43.5 MG/ML Topical Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Tavaborole Topical
Tavaborole topical solution is used to treat fungal toenail infections (infections that may cause nail discoloration, splitting, or pain). Tavaborole topical solution is in a class of medications called antifungals. It works by stopping the growth of nail fungus.
[Learn More]
* Please review the full disclaimer at the bottom of this page.